Rabeprazole Sodium Market Research, 2031
The global rabeprazole sodium market was valued at $615.7 million in 2021, and is projected to reach $895.9 million by 2031, growing at a CAGR of 3.8% from 2022 to 2031. Rabeprazole is used to treat duodenal ulcers, Zollinger-Ellison syndrome, and gastroesophageal reflux disease (GERD). In addition, it can be used in conjunction with medications to treat ulcers caused by H. pylori bacterial infections (such as amoxicillin and clarithromycin). Rabeprazole, a proton pump inhibitor (PPI), lessens the amount of stomach acid produced. It inhibits the gastric H+/K+ATPase (hydrogen-potassium adenosine triphosphatase) at the secretory surface of the gastric parietal cell.
Historical overview
The market was analyzed qualitatively and quantitatively from 2021-2031. The rabeprazole sodium market grew at a CAGR of around 4.6% during 2022-2031. Most of the growth during this period was derived from the Asia-Pacific owing to the improving health awareness, rising disposable incomes, as well as the well-established presence of domestic companies in the region.
Market dynamics
The amount of acid produced by your stomach is decreased by rabeprazole. Heartburn, acid reflux, and gastroesophageal reflux disease are all commonly treated with it. GORD is when acid reflux occurs repeatedly. Additionally, stomach ulcers can be prevented and treated with rabeprazole. Thus, increase in prevalence of digestive problems drives the market growth. According to the National Library of Medicine, GORD is one of the most common gastrointestinal disorders, with a prevalence of approximately 20% of adults in western culture. A systematic review by El-Serag et al. estimated the prevalence of GERD in the US between 18.1% to 27.8%. Thus, increase in digestive system disorders drives the rabeprazole sodium industry.
The gastrointestinal (GI) systems of senior persons constantly undergo changes, and while some GI issues are more prevalent in this age range, no GI disorder is unique to the elderly. While some of the changes to the GI system brought on by aging are physiological, others are pathological and are more prevalent in adults over the age of 65. Even though the prevalence of gastroesophageal reflux disease (GERD) increases with age. For instance, according to the Organization for Economic Co-operation and Development (OECD), the elderly population is defined as people aged 65 and over. The total percentage of the elderly population in 2020 for Japan was the highest in the world at about 28.8%. Thus, surge in the geriatric population along with foreign investments in this region propels the rabeprazole sodium industry.
In the present period, people's lifestyles are rapidly changing; they are going toward a new, unhealthy way of life that includes an unhealthy diet. An increasingly inadequate diet is the cause of an increase in digestive and intestinal issues. Gastrointestinal disorders can be effectively treated with rabeprazole sodium. Eating a diet low in fibre, not getting enough exercise, travelling or other routine changes, consuming a lot of dairy products, stress, and other lifestyle changes are some of the factors that contribute to digestive difficulties. The market is growing as a result of the rise in gastrointestinal disorders brought on by peoples' changing lifestyles. For an instance, according to national library of medicine Approximately 50% (over 3 billion) of the world populations are known to be infected with Helicobacter pylori, mainly in the developing countries. Among those, hundreds of millions of people develop peptic ulceration during their lifetime and still tens of millions might progress to gastric cancer. Thus high incidence of stomach infections propels the rabeprazole sodium market opportunity.
According to National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). GERD can affect any child. Children who are obese, overweight, or have a big waist size are more likely to have GERD. GERD is also more prevalent in children who have certain diseases that affect the oesophagus, neurological system, or lungs. Increase in consumption of acidic foods, adoption of unhealthy lifestyle is the major factor in this age group that drives the market. Eating lifestyle has a significant influence on digestive health of human beings. The global population regardless of gender follow unhealthy lifestyle and encounter illness and other health issues. Some of the worst foods known for digestion include fried foods and artificial sugars. In addition, intake of alcohol can increase chances of heartburn. According to Southgate Medical Centre, in Australia, 35% of an average adult’s daily energy intake and 41% of children’s daily energy intake comes from junk food. Hence, inclusions of unhealthy lifestyle drive the rabeprazole sodium market growth.
Workflows in the healthcare industry have been affected worldwide by the COVID-19 pandemic. The disease has compelled a number of industries, including a number of areas of health care, to temporarily close their doors. Currently, morbidity and death is prevented or reduced by vaccination, but essential public health interventions (test, track, isolate, and treat) and COVID-appropriate social behavior must still be practiced. the COVID-19 outbreak is anticipated to have a negative impact on the growth of the global rabeprazole sodium market. Moreover, the lockdown led to disruption of manufacturing and transportation of healthcare essentials. Furthermore, other factors responsible for the impact on the market include limited availability of medical care, shortage of healthcare staff, and rise in burden of COVID-19 related hospitalization
Segmental Overview
The global rabeprazole sodium market is segmented on the basis of application, age distribution channel, and region. On the basis of type, the market is categorized into gastroesophageal reflux disease treatment, duodenal ulcer treatment and others. By distribution channel, it is segmented into hospital pharmacies, drug & retail store and online providers. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and Latin America, the Middle East, and Africa (LAMEA).
By application
Based on application the market is divided into gastroesophageal reflux disease, peptic ulcer and others. The gastroesophageal reflux disease segment dominated the rabeprazole sodium market size in 2021 and is expected to witness highest CAGR during the forecast period, owing to rise in prevalence of gastroesophageal reflux disease (GERD). For instance, according to National Library of Medicine Gastroesophageal reflux disease (GERD) is the most common disorder seen in the elder population. According to an article published by National Library of Medicine, in May 2022, there was 783.95 million cases of GERD globally in 2019. Thus, rise in prevalence of Gastroesophageal reflux disease (GERD) drive the segment growth.
By Application
Gastroesophageal reflux disease segment dominated the market in 2021, and is expected to be lucrative during the forecast period
By age
Based on age the market is segmented into below 55 years and Above 55 years. The below 55 years segment dominated the rabeprazole sodium market size in 2021 and is expected to witness highest CAGR during the forecast period owing to rise in consumption of acidic foods, adoption of unhealthy lifestyle is the major factor in this age group. In addition, intake of alcohol can increase chances of heartburn in this age group further drive the market growth.
By distribution channel
The market is classified into hospital pharmacies, drug & retail store pharmacies, and online providers. The drug & retail store pharmacies segment dominated the rabeprazole sodium market share in 2021, owing to large number of patient visits to the drug & retail store pharmacies as they offer the precise drug according to status of disease of patient and easy accessibility of the facilities, The online providers segment is expected to witness highest CAGR during the rabeprazole sodium market forecast period owing to rise in digitalization around the globe and availability of rabeprazole sodium drug in online.
By region
The rabeprazole sodium market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for a major rabeprazole sodium market share in 2021, and is expected to maintain its dominance during the forecast period.
Presence of several major players, such as Eisai Inc., Woodward Pharma and advancement in manufacturing technology of rabeprazole sodium in the region drive the growth of the market. In addition, surge in ÑоnÑеrn аmоng реорlе fоr mаіntаіnÑ–ng а hеаlthу lÑ–fеѕtуlе аnd ÑоnÑ•Ñ–Ñ•tеnt grоwth Ñ–n thе gеrіаtrÑ–Ñ Ñ€Ð¾Ñ€ulаtіоn, Ñ–nÑrеаѕеѕ thе dеmаnd fоr rabeprazole sodium in the region, which is ехреÑtеd tо Ñ€rореl the grоwth оf thе mаrkеt. Furthermore, presence of well-established healthcare infrastructure, high purchasing power, and rise in adoption rate of rabeprazole sodium are expected to drive the market growth. Furthermore, product launch, mergers, collaborations, and acquisitions adopted by the key players in this region boost the growth of the market.
Asia-Pacific expected to grow at the highest rate during the forecast period. The market growth in this region is attributable to presence of pharmaceutical companies in the region as well as growth in the purchasing power of populated countries, such as China and India. Moreover, rise in medicine expenditure and adoption ofhealthy lifestyle, drive the growth of the market. Furthermore, the Asia-Pacific region exhibits the largest medicine supply and the largest pharmaceuticals industry with availability of raw material in abundance, which can be easily accessed by manufacturers of rabeprazole sodium. This, in turn, drives the growth of the market. Asia-Pacific offers profitable opportunities for key players operating in the rabeprazole sodium market, thereby registering the fastest growth rate during the forecast period, owing to the growing infrastructure of industries, rising disposable incomes, as well as well-established presence of domestic companies in the region. In addition, rise in contract manufacturing organizations within the region provides great opportunity for new entrants in this region.
COMPETITION ANALYSIS
Competitive analysis and profiles of the major players in the rabeprazole sodium market, such as
Alembic Pharmaceuticals Ltd, Cadila Pharmaceuticals Ltd, Cipla Ltd, Dr. Reddy's Laboratories Ltd, Elikem Pharmaceuticals Pvt Ltd, Jasco Labs Private Limited, Intas Pharmaceutical Ltd., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., and Woodward Pharma.
Acquisition: In November 2021, AcipHex delayed-release tablets were acquired from Eisai Co., Ltd. by Woodward Pharma, a specialised pharmaceutical firm with headquarters in Michigan with a focus on purchasing, licensing, and commercializing branded and generic pharmaceuticals for the American market. In accordance Woodward has rights to sell AcipHex in the U.S.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the rabeprazole sodium market analysis from 2021 to 2031 to identify the prevailing rabeprazole sodium market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the rabeprazole sodium market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global rabeprazole sodium market trends, key players, market segments, application areas, and market growth strategies.
Rabeprazole Sodium Market Report Highlights
| Aspects | Details |
 Market Size By 2031 | USD 895.9 million |
 Growth Rate | CAGR of 3.8% |
 Forecast period | 2021 - 2031 |
 Report Pages | 191 |
 By Application |
|
 By Age |
|
 By Distribution channel |
|
 By Region |
|
 Key Market Players | Woodward Pharma, Cipla Ltd, Sun Pharmaceutical Industries Ltd., Cadila Pharmaceuticals Ltd, Intas Pharmaceutical, Ltd., Jasco Labs Private Limited, Dr. Reddy's Laboratories Ltd, Alembic Pharmaceuticals Ltd, Elikem Pharmaceuticals Pvt Ltd, Torrent Pharmaceuticals Ltd |
Analyst Review
This section provides opinions of top level CXOs in the global rabeprazole sodium market. According to the insights of CXOs, leading companies in the market, development of advanced and reliable rabeprazole sodium formulations has led to extensive number of applications of this drug. Increase in prevalence of gastrointestinal diseases and surge in awareness for healthy lifestyle are expected to propel the growth of the rabeprazole sodium market.
The market is experiencing growth at a steady rate in developed nations. Asia-Pacific and LAMEA are expected to offer high growth opportunities to key players in the market. According to the perspectives of CXOs of leading companies in the market, significant advancements in the rabeprazole sodium market with increase in clinically backed research, growing investments, funds, and grants, entry of new players, and growth in the geriatric population is projected to increase the sale of rabeprazole sodium globally
People's lifestyles are rapidly changing; they are going toward a new, unhealthy way of life that includes an unhealthy diet. An increasingly inadequate diet is the cause of an increase in digestive and intestinal issues. Gastrointestinal disorders can be effectively treated with rabeprazole sodium.
The gastroesophageal reflux disease is the leading application of rabeprazole sodium market.
Alembic Pharmaceuticals Ltd, Cadila Pharmaceuticals Ltd, Cipla Ltd, Dr. Reddy's Laboratories Ltd, Elikem Pharmaceuticals Pvt Ltd, Jasco Labs Private Limited, Intas Pharmaceutical Ltd., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., and Woodward Pharma are the top companies to hold the market share in rabeprazole sodium market.
North America is the largest regional market for rabeprazole sodium market.
The global rabeprazole sodium market was valued at $615.72 million in 2021, and is estimated to reach $895.85 million by 2031, growing at a CAGR of 3.8% from 2022 to 2031.
2021 is the base year of rabeprazole sodium market.
2022 to 2031 is the forecast period of rabeprazole sodium market.
Loading Table Of Content...
